Study identifier:D4300C00005
ClinicalTrials.gov identifier:N/A
EudraCT identifier:2010-020892-22
CTIS identifier:N/A
(OSKIRA-X): A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Rheumatoid Arthritis
Rheumatoid Arthritis
Phase 3
No
Fostamatinib
All
1917
Interventional
18 Years - 150 Years
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Apr 2014 by AstraZeneca
AstraZeneca
-
The purpose of this study is to evaluate the long term safety and tolerability of fostamatinib in patients with rheumatoid arthritis (RA).
Location
Location
Buenos Aires, Argentina
Location
Ciudad de Buenos Aires, Argentina
Location
Ciudad Autónoma Bs As, Argentina
Location
San Miguel de Tucuman, Argentina
Location
Rosario, Argentina
Location
Ciudad Autonoma Bs As, Argentina
Location
San Juan, Argentina
Location
Cordoba, Argentina
Arms | Assigned Interventions |
---|---|
Experimental: A Oral treatment | Drug: Fostamatinib Fostamatinib 100mg twice daily |
Experimental: B Oral treatment | Drug: Fostamatinib Fostamatinib 150mg once daily |
Experimental: C Oral treatment | Drug: Fostamatinib Fostamatinib 100mg once daily |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.